Bibliography
- Alonso J , AngermeyerMC, BernertSet al.: Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project.Acta Psychiatr. Scand. Suppl.21–27 (2004).
- Evans DL , StaabJP, PetittoJMet al.: Depression in the medical setting: biopsychological interactions and treatment considerations.J. Clin. Psychiatry60(Suppl. 4), S40–S55 (1999).
- Anderson IM , NuttDJ, DeakinJF: Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines.J. Psychopharm.14, 3–20 (2000).
- National Institute for Clinical Excellence: depression: management of depression in primary and secondary care. Clinical Guideline23, (2004).
- McAllister-Williams RH : NICE Guidelines for the management of depression.Brit. J. Hosp. Med.67, 60–61 (2006).
- Einarson TR , ArikianSR, CascianoJet al.: Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.Clin. Ther.21, 296–308 (1999).
- Thase ME , EntsuahAR, RudolphRL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.Br. J. Psychiatry178, 234–241 (2001).
- Smith D , DempsterC, GlanvilleJet al.: Efficacy and tolerability of venlafaxine compared to selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.Br. J. Psychiatry180, 396–404 (2002).
- Thase ME : Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients.J. Clin. Psychiatry59, 502–508 (1998).
- Mackay FR , DunnNR, MartinRMet al.: Newer antidepressants: a comparison of tolerability in general practice.Br. J. Gen. Pract.49, 892–896 (1999).
- Buckley NA , McManusPR: Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data.Br. Med. J.325, 1332–1333 (2002).
- Mines D , HillD, YuHet al.: Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram.Pharmacoepidem. & Drug Safety14, 367–372 (2005).
- Bymaster FP , LeeTC, KnadlerMPet al.: The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.Current Pharmaceutical Design11, 1475–1493 (2005).
- Chalon SA , GranierLA, VandenhendeFRet al.: Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharm.28, 1685–1693 (2003).
- Anttila S , LeinonenE: Duloxetine.Curr. Opin. Investig. Drugs3, 1217–1221 (2002).
- Wong DT , BymasterFP: Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?Prog. Drug Res.58, 169–222 (2002).
- Koch S , Hemrick-LueckeSK, Thompson LKet al.: Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharm.45, 935–944 (2003).
- Bitsios P , SzabadiE, BradshawCM: Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man.Psychopharm.143, 286–292 (1999).
- Lantz RJ , GillespieTA, RashTJet al.: Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.Drug Metab. & Disposition31, 1142–1150 (2003).
- Glueck CJ , KhalilQ, WiniarskaMet al.: Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio.JAMA295, 1517–1518 (2006).
- Sharma A , GoldbergMJ, CerimeleBJ: Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.J. Clin. Pharmacol.40, 161–167 (2000).
- Skinner MH , KuanHY, SkerjanecAet al.: Effect of age on the pharmacokinetics of duloxetine in women. Brit.J. Clin. Pharmacol.57, 54–61 (2004).
- Cymbalta®specification of product characteristics, Eli Lilly and Co., UK (2006).
- de Leon J , ArmstrongSC, CozzaKL: Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.Psychosomatics47, 75–85 (2006).
- Skinner MH , KuanHY, PanAet al.: Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.Clin. Pharmacol. Therap.73, 170–177 (2003).
- Suri A , ReddyS, GonzalesCet al.: Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects.Int. J. Clin. Pharmacol. Therap.43, 78–84 (2005).
- Detke MJ , LuY, GoldsteinDJet al.: Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.J. Psychiat. Res.36, 383–390 (2002).
- Detke MJ , LuY, GoldsteinDJet al.: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.J. Clin. Psychiatry63, 308–315 (2002).
- Hirschfeld RM , MallinckrodtC, LeeTCet al.: Time course of depression-symptom improvement during treatment with duloxetine. Depression & Anxiety21, 170–177 (2005).
- Silverstone PH , EntsuahR, HackettD: Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine.Int. Clin. Psychopharmacol.17, 273–280 (2002).
- Goldstein DJ , LuY, DetkeMJet al.: Duloxetine vs. placebo in patients with painful diabetic neuropathy.Pain116, 109–118 (2005).
- Arnold LM , LuY, CroffordLJet al.: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.Arth & Rheum.50, 2974–2984 (2004).
- Arnold LM , RosenA, PritchettYLet al.: A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.Pain119, 5–15 (2005).
- Kroenke K , SpitzerRL, WilliamsJBet al.: Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment.Arch. Family Med.3, 774–779 (1994).
- Ohayon MM , SchatzbergAF: Using chronic pain to predict depressive morbidity in the general population.Arch. Gen. Psychiatry60, 39–47 (2003).
- Bair MJ , RobinsonRL, EckertGJet al.: Impact of pain on depression treatment response in primary care.Psychosom. Med.66, 17–22 (2004).
- Bomholt SF , MikkelsenJD, Blackburn-MunroG: Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain.Neuropharm.48, 252–263 (2005).
- Barkin RL , BarkinS: The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy.Am. J. Ther.12, 431–438 (2005).
- Fava M , MallinckrodtCH, DetkeMJet al.: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?J. Clin. Psychiatry.65, 521–530 (2004).
- Nelson JC , WohlreichMM, Mallinckrodt CHet al.: Duloxetine for the treatment of major depressive disorder in older patients. American Journal of Geriatric Psychiatry13, 227–235 (2005).
- Raskin J , WiltseC, DinkelJet al.: Duloxetine versus placebo in the treatment of elderly patients with major depressive disorder. Poster presented at American Association for Geriatric Psychiatry (2005).
- Perahia DG , GilaberteI, WangFet al.: Duloxetine in the prevention of relapse of major depressive disorder.Br. J. Psychiatry188, 346–353 (2006).
- Goldstein DJ , LuY, DetkeMJet al.: Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.J. Clin. Psychopharmacol24, 389–399 (2004).
- Detke MJ , WiltseCG, MallinckrodtCHet al.: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharm.14, 457–470 (2004).
- Thase ME , LuY, JoliatJet al.: Remission in placebo-controlled trials of duloxetine with an SSRI comparator. Presented at:International Forum for Mood and Anxiety Disorders, November 19–21, 2003, Monte Carlo, Monaco (2003).
- Perahia DG , PritchettYL, WalkerDet al.: Comparing duloxetine and venlafaxine in the treatment of major depressive disorder using a global benefit-risk approach. Presented at:New Clinical Drug Evaluation Unit (NCDEU), June 6–9, 2005, Boca Raton, FL, USA (2005).
- Entsuah R , GormanJM: Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine.J. Psychiatric Res.36, 111–118 (2002).
- Hudson JI , WohlreichMM, KajdaszDKet al.: Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Human Psychopharm.20, 327–341 (2005).
- Delgado PL , BrannanSK, MallinckrodtCHet al.: Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.J. Clin. Psychiatry66, 686–692 (2005).
- Thase ME , GandhiP, BarradellKet al.: The Cardiovascular Safety Profile of Duloxetine, A Serotonin and Noradrenalin Reuptake Inhibitor. Presented at:Royal College of Psychiatrists Liasion Section February, Cambridge, UK (2004).
- Stahl SM , GradyMM, MoretCet al.: SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.CNS Spectrums10, 732–747 (2005).
- Dunner DL , WohlreichMM, Mallinckrodt CHet al.: Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg QD starting doses. Curr. Ther. Res. Clin. Exp.66, 522–540 (2005).
- Wohlreich MM , MartinezJM, Mallinckrodt CHet al.: An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J. Clin. Psychopharmacol.25, 552–560 (2005).
- Hanje AJ , PellLJ, VotolatoNAet al.: Case report: fulminant hepatic failure involving duloxetine hydrochloride.Clin. Gastroenterol. Hepatol.4, 912–917 (2006).
- Perahia DG , KajdaszDK, DesaiahDet al.: Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.J. Affect. Disord.89, 207–212 (2005).
- Poirier MF , BoyerP: Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.Br. J. Psychiatry175, 12–16 (1999).
- National Institute for Clinical Excellence: Bipolar Disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Clinical Guideline38, (2006).